Blog
RSS FeedPosted by Michael Wonder on 04 Nov 2023
Hormone replacement therapy patch shortages are having a big impact on the women who need them
4 November 2023 - Women are being thrust back into the most severe stages of menopause amid long-running national shortages of ...
Posted by Michael Wonder on 18 Oct 2021
Australia secures additional COVID-19 treatments
17 October 2021 - The Australian Government has secured access to two additional COVID-19 treatments to support the National Plan to ...
Posted by Michael Wonder on 10 Nov 2020
Mirum Pharmaceuticals broadens Expanded Access Program for maralixibat in Alagille syndrome to Europe and Australia
5 November 2020 - Maralixibat Expanded Access Program now available for patients with pruritus associated with Alagille syndrome in Australia and ...
Posted by Michael Wonder on 18 Apr 2018
2018 influenza vaccines now available
18 April 2018 - More than 4.5 million Australians who are most at risk of getting sick during this year’s flu ...
Posted by Michael Wonder on 05 Aug 2015
Specialised Therapeutics Australia receives TGA approval for Abraxane in combination with gemcitabine for first-line treatment of metastatic pancreatic cancer
Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that Abraxane (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in ...
Posted by Michael Wonder on 05 Aug 2015
Biogen Idec's Plegridy approved for Australian adults with relapsing multiple sclerosis
Biogen Idec is pleased to announce that Plegridy (peginterferon beta-1a) has been approved by the Therapeutic Goods Administration (TGA) for treatment of adults ...
Posted by Michael Wonder on 05 Aug 2015
Actelion receives Therapeutic Goods Administration approval in Australia for Opsumit (macitentan) in pulmonary arterial hypertension
Actelion Ltd today announced the approval of Opsumit (macitentan) for the treatment of pulmonary arterial hypertension (PAH) by the Therapeutic ...
Posted by Michael Wonder on 05 Aug 2015
EMA and Australian regulatory authority strengthen collaboration in the area of orphan medicines
At a meeting at the European Medicines Agency (EMA) office on 4 April 2014, the EMA's Executive Director Prof Guido ...
Posted by Michael Wonder on 05 Aug 2015
Protalix announces Elelyso (taliglucerase alfa) approved in Australia for the treatment of Gaucher disease in both adult and paediatric patients
22 May 2014 - Protalix BioTherapeutics, Inc. announced today that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval to Elelyso (taliglucerase alfa) for long-term enzyme ...